BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 10560359)

  • 1. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
    Zweemer RP; Shaw PA; Verheijen RM; Ryan A; Berchuck A; Ponder BA; Risch H; McLaughlin JR; Narod SA; Menko FH; Kenemans P; Jacobs IJ
    J Clin Pathol; 1999 May; 52(5):372-5. PubMed ID: 10560359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.
    Rhei E; Bogomolniy F; Federici MG; Maresco DL; Offit K; Robson ME; Saigo PE; Boyd J
    Cancer Res; 1998 Aug; 58(15):3193-6. PubMed ID: 9699640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
    Boyd J; Sonoda Y; Federici MG; Bogomolniy F; Rhei E; Maresco DL; Saigo PE; Almadrones LA; Barakat RR; Brown CL; Chi DS; Curtin JP; Poynor EA; Hoskins WJ
    JAMA; 2000 May; 283(17):2260-5. PubMed ID: 10807385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
    Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
    Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
    Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer.
    Welcsh PL; King MC
    Hum Mol Genet; 2001 Apr; 10(7):705-13. PubMed ID: 11257103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
    Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
    Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations.
    Khoo US; Ngan HY; Cheung AN; Chan KY; Lu J; Chan VW; Lau S; Andrulis IL; Ozcelik H
    Hum Mutat; 2000 Jul; 16(1):88-9. PubMed ID: 10874312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
    Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
    J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours.
    Ramus SJ; Bobrow LG; Pharoah PD; Finnigan DS; Fishman A; Altaras M; Harrington PA; Gayther SA; Ponder BA; Friedman LS
    Genes Chromosomes Cancer; 1999 Jun; 25(2):91-6. PubMed ID: 10337991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations.
    Wang-Gohrke S; Weikel W; Risch H; Vesprini D; Abrahamson J; Lerman C; Godwin A; Moslehi R; Olipade O; Brunet JS; Stickeler E; Kieback DG; Kreienberg R; Weber B; Narod SA; Runnebaum IB
    Br J Cancer; 1999 Sep; 81(1):179-83. PubMed ID: 10487631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.
    Rubin SC; Blackwood MA; Bandera C; Behbakht K; Benjamin I; Rebbeck TR; Boyd J
    Am J Obstet Gynecol; 1998 Apr; 178(4):670-7. PubMed ID: 9579428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hereditary breast and ovarian cancer].
    Lax SF
    Pathologe; 2017 May; 38(3):149-155. PubMed ID: 28500412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
    Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET
    J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
    Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinosarcoma of the ovary in a patient with a germline BRCA2 mutation: evidence for monoclonal origin.
    Sonoda Y; Saigo PE; Federici MG; Boyd J
    Gynecol Oncol; 2000 Feb; 76(2):226-9. PubMed ID: 10637076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
    Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
    Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.